Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CP 532,623

Known as: CP532623, CP-532623, CP 532623 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Quinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
Lipid based formulations (LBFs) are a promising formulation strategy for many poorly water-soluble drugs and have been shown… Expand
Is this relevant?
2014
2014
In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623.
The present study investigated the use of lipid based drug delivery systems to enhance the oral bioavailability of the CETP… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
The Role of the Intestinal Lymphatics in the Absorption of Two Highly Lipophilic Cholesterol Ester Transfer Protein Inhibitors (CP524,515 and CP532,623)
ABSTRACTPurposeTo evaluate the potential role of intestinal lymphatic transport in the absorption and oral bioavailability of… Expand
  • table I
  • figure 1
  • table II
  • table III
  • figure 2
Is this relevant?
2009
2009
Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
ILLUMINATE, the phase 3 morbidity and mortality trial of the cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE